

# James C Coons

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5838196/publications.pdf>

Version: 2024-02-01

55  
papers

1,339  
citations

448610

19  
h-index

425179

34  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1945  
citing authors

#	ARTICLE	IF	CITATIONS
1	An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12003.	0.8	4
2	<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. <i>Journal of the American Heart Association</i> , 2022, 11, e024159.	1.6	24
3	A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations. <i>Annals of Pharmacotherapy</i> , 2021, 55, 618-623.	0.9	2
4	Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 705-715.	2.3	25
5	A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110136.	1.0	4
6	Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 341-348.	1.0	17
7	Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure. <i>Current Cardiology Reports</i> , 2021, 23, 27.	1.3	7
8	Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 430-449.	0.8	12
9	Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. <i>Pharmacotherapy</i> , 2020, 40, 204-210.	1.2	58
10	Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review. <i>Pharmacotherapy</i> , 2019, 39, 929-945.	1.2	9
11	Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time. <i>American Journal of Hematology</i> , 2019, 94, 1015-1019.	2.0	14
12	Development of best practice recommendations for the safe use of pulmonary hypertension pharmacotherapies using a modified Delphi method. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 153-165.	0.5	8
13	Engaging and Empowering Stakeholders to Advance Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 305-308.	2.3	5
14	Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 303-313.	0.5	45
15	Effect of Selective Serotonin Reuptake Inhibitors on Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study. <i>Clinical Drug Investigation</i> , 2019, 39, 543-551.	1.1	11
16	Evidence for simulation in pharmacy education. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 686-692.	0.5	33
17	Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. <i>Current Cardiology Reports</i> , 2019, 21, 141.	1.3	51
18	Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers. <i>Journal of Interventional Cardiology</i> , 2019, 2019, 1-6.	0.5	30

#	ARTICLE	IF	CITATIONS
19	A Pharmacotherapy Scholars Program to Provide Intensive Training to Enhance Pharmacy Students'™ Postgraduate Readiness. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7327.	0.7	9
20	Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661876649.	1.0	8
21	Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 310-316.	0.7	36
22	Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 664-674.	2.3	94
23	Multisite Investigation of Outcomes With Implementation of <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	1.1	213
24	Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-4.	0.8	3
25	Virtual Electronic Health Record Technology with Simulation-Based Learning in an Acute Care Pharmacotherapy Course. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 123.	0.6	14
26	Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 546-551.	1.0	28
27	Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. <i>Annals of Pharmacotherapy</i> , 2017, 51, 649-655.	0.9	6
28	Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support. <i>Pharmacotherapy</i> , 2017, 37, 1272-1283.	1.2	26
29	Pulmonary Arterial Hypertension. , 2017, , .		0
30	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Transitioned from Parenteral or Inhaled Prostacyclins: Case Series and Treatment Protocol. <i>Pulmonary Circulation</i> , 2016, 6, 132-135.	0.8	22
31	Advancing Pharmacogenomics Education in the Core PharmD Curriculum through Student Personal Genomic Testing. <i>American Journal of Pharmaceutical Education</i> , 2016, 80, 3.	0.7	73
32	Clinical effectiveness and safety outcomes associated with prothrombin complex concentrates. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 6-10.	1.0	9
33	Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. <i>Pharmacotherapy</i> , 2015, 35, 1164-1172.	1.2	18
34	Pharmacotherapy Update of Acute Idiopathic Pericarditis. <i>Pharmacotherapy</i> , 2015, 35, 99-111.	1.2	15
35	Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 249-260.	1.0	123
36	Ticagrelor Use in a Patient With a Documented Clopidogrel Hypersensitivity. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1230-1233.	0.9	10

#	ARTICLE	IF	CITATIONS
37	Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations. <i>Pharmacotherapy</i> , 2014, 34, 973-990.	1.2	2
38	An evidence based systematic review of remifentanyl associated opioid-induced hyperalgesia. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 587-603.	1.0	42
39	Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 609-620.	1.5	3
40	Role of Phosphodiesterase-5 Inhibitors in Heart Failure: Emerging Data and Concepts. <i>Current Heart Failure Reports</i> , 2013, 10, 26-35.	1.3	15
41	Safe and effective use of prostacyclins to treat pulmonary arterial hypertension. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1716-1723.	0.5	5
42	Transitioning from Parenteral Treprostinil to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 116-120.	0.8	10
43	Pharmacotherapy for acute heart failure syndromes. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 21-35.	0.5	34
44	Comment: Worsening Heart Failure in the Setting of Dronedaronc Initiation. <i>Annals of Pharmacotherapy</i> , 2011, 45, 690-690.	0.9	0
45	Thrombolytics/Anticoagulants. , 2011, , 1-67.		0
46	Worsening Heart Failure in the Setting of Dronedaronc Initiation. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1496-1500.	0.9	14
47	Takotsubo cardiomyopathy. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 562-566.	0.5	8
48	2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies. <i>Annals of Pharmacotherapy</i> , 2008, 42, 989-1001.	0.9	14
49	Cardiovascular Pharmacotherapy Update for the Intensive Care Unit. <i>Critical Care Nursing Quarterly</i> , 2007, 30, 44-57.	0.4	6
50	Multidisciplinary team for enhancing care for patients with acute myocardial infarction or heart failure. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 1274-1278.	0.5	24
51	Treatment of Heparin-Induced Thrombocytopenia: Is There a Role for Bivalirudin?. <i>Pharmacotherapy</i> , 2006, 26, 229-241.	1.2	18
52	Outcomes and Costs of Abciximab Versus Eptifibatide for Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1621-1626.	0.9	12
53	Eptifibatide-Associated Acute, Profound Thrombocytopenia. <i>Annals of Pharmacotherapy</i> , 2005, 39, 368-372.	0.9	34
54	Terbutaline for Chronotropic Support in Heart Transplantation. <i>Annals of Pharmacotherapy</i> , 2004, 38, 586-589.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitors in Osteoporosis Management. <i>Annals of Pharmacotherapy</i> , 2002, 36, 326-330.	0.9	27